Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
Anti-Bacterial Agents
/ pharmacokinetics
Cephalosporins
/ pharmacokinetics
Colistin
/ pharmacokinetics
Drug Resistance, Multiple, Bacterial
/ drug effects
Humans
Microbial Sensitivity Tests
Models, Biological
Pseudomonas Infections
/ drug therapy
Pseudomonas aeruginosa
/ drug effects
Tazobactam
/ pharmacokinetics
beta-Lactam Resistance
/ drug effects
Pseudomonas aeruginosa
ceftolozane-tazobactam
colistin
combination therapy
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
24 03 2020
24 03 2020
Historique:
received:
19
12
2019
accepted:
30
01
2020
pubmed:
12
2
2020
medline:
23
2
2021
entrez:
12
2
2020
Statut:
epublish
Résumé
Combination therapy is an attractive therapeutic option for extensively drug-resistant (XDR)
Identifiants
pubmed: 32041712
pii: AAC.02542-19
doi: 10.1128/AAC.02542-19
pmc: PMC7179322
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
ceftolozane, tazobactam drug combination
0
Tazobactam
SE10G96M8W
Colistin
Z67X93HJG1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Int J Antimicrob Agents. 2016 Dec;48(6):725-727
pubmed: 28128096
Lancet Infect Dis. 2006 Sep;6(9):589-601
pubmed: 16931410
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530842
Clin Microbiol Rev. 2015 Jan;28(1):191-207
pubmed: 25567227
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Int J Antimicrob Agents. 2019 May;53(5):612-619
pubmed: 30682497
Clin Microbiol Infect. 2018 Jul;24(7):689-696
pubmed: 29269090
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
pubmed: 23458769
Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1457-1461
pubmed: 31073653
Sci Rep. 2019 Jan 24;9(1):487
pubmed: 30679735
J Antimicrob Chemother. 2018 Apr 1;73(4):942-952
pubmed: 29272436
J Antimicrob Chemother. 2017 Oct 1;72(10):2813-2816
pubmed: 29091209
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29483119
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31358583
Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8
pubmed: 23774429
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
J Antimicrob Chemother. 2007 Dec;60(6):1206-15
pubmed: 17878146
Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95
pubmed: 21911563
Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6
pubmed: 19433570
J Chromatogr Sci. 2016 Jul;54(6):1037-40
pubmed: 27048639
Drugs. 2014 Jan;74(1):31-51
pubmed: 24352909
Infection. 2009 Oct;37(5):461-5
pubmed: 19499183
BMC Infect Dis. 2013 Aug 19;13:380
pubmed: 23957376
Clin Exp Optom. 2018 Mar;101(2):162-171
pubmed: 29044738
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93
pubmed: 26711759
J Chromatogr B Biomed Sci Appl. 2001 Sep 25;761(2):167-75
pubmed: 11587346
Antimicrob Agents Chemother. 1978 Apr;13(4):570-6
pubmed: 352258
J Antimicrob Chemother. 2018 Sep 1;73(9):2411-2417
pubmed: 30020472
J Infect Dis. 2015 Apr 15;211(8):1326-33
pubmed: 25362196
Drug Resist Updat. 2015 Jul-Aug;21-22:41-59
pubmed: 26304792
Antimicrob Agents Chemother. 2012 Jan;56(1):231-42
pubmed: 22005996
J Glob Antimicrob Resist. 2019 Sep;18:37-44
pubmed: 31154007
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30249700
Antimicrob Agents Chemother. 2010 Jun;54(6):2646-54
pubmed: 20368395
Antimicrob Agents Chemother. 2015 May;59(5):2515-24
pubmed: 25691628
Clin Microbiol Rev. 2019 Aug 28;32(4):
pubmed: 31462403
Infect Dis Clin North Am. 2016 Jun;30(2):441-464
pubmed: 27208767
BMC Infect Dis. 2017 Jan 5;17(1):11
pubmed: 28056821
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28874376
Clin Infect Dis. 2016 Mar 1;62(5):552-558
pubmed: 26607424